- A Comparative Study of Topical Mitomycin C, Cyclosporine, and Bevacizumab after Primary Pterygium Surgery
-
Hwang S, Choi S
- KMID: 2363844
- Korean J Ophthalmol.
- 2015 Dec;29(6):375-381.
- doi: 10.3341/kjo.2015.29.6.375
PURPOSE: To compare the recurrence rates and complications associated with instillation of topical mitomycin C, cyclosporine, and bevacizumab after primary pterygium surgery. METHODS: Between July 2013 and June 2014, we performed... -
- CITED
-
- Close
- SHARE
-
- Close
- Intravitreal Bevacizumab for the Treatment of Optic Disc Edema in a Patient with POEMS Syndrome
-
Kim DW, Kang SY, Bae HW, Hong S, Seong GJ, Kim CY
- KMID: 2363812
- Korean J Ophthalmol.
- 2015 Oct;29(5):354-356.
- doi: 10.3341/kjo.2015.29.5.354
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Optic Disc Edema Responding to Localized Anti-vascular Endothelial Growth Factor Treatment in a Patient with POEMS Syndrome
-
Song HB, Yu HG
- KMID: 2363813
- Korean J Ophthalmol.
- 2015 Oct;29(5):357-358.
- doi: 10.3341/kjo.2015.29.5.357
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Assessment of Patient Pain Experience during Intravitreal 27-Gauge Bevacizumab and 30-Gauge Ranibizumab Injection
-
Guler M, Bilgin B, Capkin M, Simsek A, Bilak S
- KMID: 2363758
- Korean J Ophthalmol.
- 2015 Jun;29(3):190-194.
- doi: 10.3341/kjo.2015.29.3.190
PURPOSE: To compare pain scores of patients during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection procedures. METHODS: Seventy eyes of 70 patients who had not previously undergone intravitreal anti-vascular endothelial growth... -
- CITED
-
- Close
- SHARE
-
- Close
- Angiographically Documented Macular Ischemia after Single Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion
-
Lee KH, Kang EC, Koh HJ
- KMID: 2419132
- Yonsei Med J.
- 2017 May;58(3):676-678.
- doi: 10.3349/ymj.2017.58.3.676
This report describes a case of angiographically documented foveal avascular zone (FAZ) enlargement after a single intravitreal injection of bevacizumab for macular edema secondary to central retinal vein occlusion (CRVO).... -
- CITED
-
- Close
- SHARE
-
- Close
- High Dose Intravitreal Bevacizumab for Refractory Pigment Epithelial Detachment in Age-related Macular Degeneration
-
Lee DK, Kim SH, You YS, Kwon OW
- KMID: 2373986
- Korean J Ophthalmol.
- 2016 Aug;30(4):265-271.
- doi: 10.3341/kjo.2016.30.4.265
PURPOSE: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) is the first choice of treatment for age-related macular degeneration. However, quite a few eyes treated using conventional dose anti-VEGF (CDAV) have persistent... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor
-
Kim KH, Kim JH, Chang YS, Lee TG, Kim JW, Lew YJ
- KMID: 2363805
- Korean J Ophthalmol.
- 2015 Oct;29(5):315-324.
- doi: 10.3341/kjo.2015.29.5.315
PURPOSE: To evaluate the long-term outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) monotherapy for patients diagnosed with submacular hemorrhage secondary to exudative age-related macular degeneration. METHODS: This retrospective, observational study... -
- CITED
-
- Close
- SHARE
-
- Close
